

Supplemental Table S2. Subgroup Analyses according to Age, Sex, Diabetes Duration, and Use of Insulin and OHAs

Variable	Total	ESRD event, <i>n</i>	IR, /1,000 PY	Adjusted HR ^a (95% CI)	Adjusted HR ^a (95% CI)	<i>P</i> for interaction
Age <65 years						
CKD ⁻ Gout ⁻	555,870	3,717	0.73	1 (ref.)	1 (ref.)	<0.0001
CKD ⁻ Gout ⁺	15,463	167	1.20	1.43 (1.22–1.67)	1.43 (1.22–1.67)	
CKD ⁺ Gout ⁻	32,348	2,754	9.80	9.34 (8.87–9.83)	1 (ref.)	
CKD ⁺ Gout ⁺	2,181	458	26.68	19.47 (17.62–21.52)	2.09 (1.89–2.31)	
Age ≥65 years						
CKD ⁻ Gout ⁻	203,504	1,524	0.88	1 (ref.)	1 (ref.)	0.004
CKD ⁻ Gout ⁺	6,222	90	1.73	1.62 (1.31–2.00)	1.62 (1.31–2.00)	
CKD ⁺ Gout ⁻	48,877	2,641	7.00	7.18 (6.73–7.67)	1 (ref.)	
CKD ⁺ Gout ⁺	3,317	474	20.39	16.48 (14.82–18.31)	2.29 (2.08–2.53)	
Male sex						
CKD ⁻ Gout ⁻	474,196	3,706	0.88	1 (ref.)	1 (ref.)	<0.0001
CKD ⁻ Gout ⁺	17,521	219	1.42	1.52 (1.32–1.74)	1.52 (1.32–1.74)	
CKD ⁺ Gout ⁻	39,995	3,271	10.29	8.33 (7.93–8.76)	1 (ref.)	
CKD ⁺ Gout ⁺	4,247	750	24.11	17.78 (16.38–19.29)	2.13 (1.97–2.31)	
Female sex						
CKD ⁻ Gout ⁻	285,178	1,535	0.59	1 (ref.)	1 (ref.)	0.001
CKD ⁻ Gout ⁺	4,164	38	1.01	1.45 (1.05–2.00)	1.45 (1.05–2.00)	
CKD ⁺ Gout ⁻	41,230	2,124	6.24	8.97 (8.35–9.62)	1 (ref.)	
CKD ⁺ Gout ⁺	1,251	182	19.57	23.36 (19.97–27.32)	2.60 (2.24–3.03)	
Diabetes duration, <5 yr						
CKD ⁻ Gout ⁻	520,659	1,795	0.38	1 (ref.)	1 (ref.)	<0.0001
CKD ⁻ Gout ⁺	14,496	89	0.69	1.54 (1.25–1.91)	1.54 (1.25–1.91)	
CKD ⁺ Gout ⁻	42,789	1,232	3.42	8.04 (7.44–8.68)	1 (ref.)	
CKD ⁺ Gout ⁺	2,782	311	14.38	24.55 (21.62–27.87)	3.06 (2.69–3.48)	
Diabetes duration, ≥5 yr						
CKD ⁻ Gout ⁻	238,715	3,446	1.64	1 (ref.)	1 (ref.)	0.003
CKD ⁻ Gout ⁺	7,189	168	2.68	1.46 (1.25–1.70)	1.46 (1.25–1.70)	
CKD ⁺ Gout ⁻	38,436	4,163	13.96	8.8 (8.38–9.24)	1 (ref.)	
CKD ⁺ Gout ⁺	2,716	621	33.05	16.80 (15.38–18.35)	1.91 (1.75–2.08)	
No insulin use						
CKD ⁻ Gout ⁻	700,736	3,522	0.56	1 (ref.)	1 (ref.)	<0.0001
CKD ⁻ Gout ⁺	19,702	177	1.01	1.56 (1.34–1.82)	1.56 (1.34–1.82)	
CKD ⁺ Gout ⁻	68,345	2,984	5.25	8.28 (7.86–8.73)	1 (ref.)	
CKD ⁺ Gout ⁺	4,368	576	17.22	22.78 (20.79–24.96)	2.75 (2.51–3.01)	
Insulin use						
CKD ⁻ Gout ⁻	58,638	1,719	3.45	1 (ref.)	1 (ref.)	0.071
CKD ⁻ Gout ⁺	1,983	80	4.86	1.36 (1.09–1.71)	1.36 (1.09–1.71)	
CKD ⁺ Gout ⁻	12,880	2,411	26.69	8.42 (7.89–9.00)	1 (ref.)	
CKD ⁺ Gout ⁺	1,130	356	51.18	14.47 (12.86–16.27)	1.72 (1.53–1.92)	
OHA <3 agents						
CKD ⁻ Gout ⁻	644,124	3,550	0.61	1 (ref.)	1 (ref.)	<0.0001
CKD ⁻ Gout ⁺	18,167	185	1.15	1.60 (1.38–1.86)	1.60 (1.38–1.86)	
CKD ⁺ Gout ⁻	64,490	3,832	7.28	8.92 (8.49–9.37)	1 (ref.)	
CKD ⁺ Gout ⁺	4,468	749	22.79	21.58 (19.88–23.44)	2.42 (2.23–2.62)	
OHA ≥3 agents						
CKD ⁻ Gout ⁻	115,250	1,691	1.66	1 (ref.)	1 (ref.)	0.039
CKD ⁻ Gout ⁺	3,518	72	2.35	1.26 (1.00–1.60)	1.26 (1.00–1.60)	
CKD ⁺ Gout ⁻	16,735	1,563	11.85	7.43 (6.90–8.00)	1 (ref.)	
CKD ⁺ Gout ⁺	1,030	183	24.25	12.60 (10.78–14.73)	1.70 (1.45–1.98)	

Adjusted for age, sex, income, hypertension, dyslipidemia, smoking, alcohol consumption, regular exercise, body mass index, diabetes duration, and insulin, OHA, and glucose levels.

OHA, oral hypoglycemic agent; ESRD, end-stage renal disease; IR, incidence rate; PY, person-year; HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease.

^aThe adjusted HR was calculated separately for the groups with and without CKD, based on the presence or absence of gout in each group.